{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/117525838"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "The $6.2 million year over year increase results primarily from an increase in sales and marketing expenses, due to market development and commercialization activities for the BGM Galectin-3 test in the U.S. and European markets and from an increase in general and administrative expenses, mainly from personnel related costs, legal and regulatory expenses and public company related expenses." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "bg-medicine.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/26866374"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/117525838" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/412465092"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/117525838"] } } }
